Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia.
This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators.
NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing for medical containers, including vials, ampoules, pre-filled syringes, and cartridges. Demand for these containers has surged, driven by the global expansion of biopharmaceuticals. Specifically, markets for GLP-1 formulations (for diabetes and obesity treatments) are growing at approximately 33% annually*2, with rising demand across North America, Europe, and emerging regions like India and China. By establishing this high-volume, low-emission manufacturing platform, NEG aims to support these rapidly growing global needs.
Comment from Masamori Wada, Vice President:
“Launching the world’s first mass production line for pharmaceutical glass tubing using an all-electric furnace is a major milestone. We see this as a concrete step toward carbon-neutral pharmaceutical supply chains, enabling customers to choose products that are both high-grade and environmentally responsible.”
A shift in how pharmaceutical glass is made traditional glass melting uses fossil fuels, generating large amounts of CO2 and waste heat. NEG’s all-electric furnace uses its proprietary NEG Electric Melting TechnologyTM, which applies electricity to submerged electrodes to heat glass directly. This achieves high energy efficiency, eliminates combustion gas emissions, and dramatically cuts environmental impact while maintaining the high quality required for pharmaceutical glass.
*1 Estimated on the assumption that production is carried out at Nippon Electric Glass (Malaysia) Sdn. Bhd. using an all-electric melting furnace with renewable energy.
*2 Prophecy Market Insights
View source version on businesswire.com: https://www.businesswire.com/news/home/20251215772086/en/
Contacts
Company
Nippon Electric Glass Co., Ltd. (NEG)
https://www.neg.co.jp/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neg.co.jp%
2Fen%2F&esheet=54371242&newsitemid=20251215772086&lan=en-US&anchor=https%3A%2F%2
Fwww.neg.co.jp%2Fen%2F&index=1&md5=d2a46dd6e00b10dd3674e7a7421405b1
Product Inquiry
https://form.neg.co.jp/webapp/form/26624_aknb_8/index.do?term_slug=43&post_slug=
119 -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fform.neg.co.jp
%2Fwebapp%2Fform%2F26624_aknb_8%2Findex.do%3Fterm_slug%3D43%26post_slug%3D119&es
heet=54371242&newsitemid=20251215772086&lan=en-US&anchor=https%3A%2F%2Fform.neg.
co.jp%2Fwebapp%2Fform%2F26624_aknb_8%2Findex.do%3Fterm_slug%3D43%26amp%3Bpost_sl
ug%3D119&index=2&md5=21f57dc576b1444d0faa0ddc500ffbc7
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press Release
HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Crespo (Pigment), and senior leaders from global brands like Diageo, Disney, and Replit. Additional speakers represent over 20 AI unicorns, including Quantexa, Owkin, an
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press Release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press Release
Wolfspeed, Inc. (NYSE: WOLF), a global leader in silicon carbide technology, today announced a significant industry milestone with the successful production of a single crystal 300mm (12-inch) silicon carbide wafer. Backed by one of the industry’s largest and foundational silicon carbide IP portfolios, comprising more than 2,300 issued and pending patents worldwide, Wolfspeed is pioneering the transition to 300mm technology, establishing a clear path to future volume commercialization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113487095/en/ Wolfspeed produces 300mm silicon carbide wafer. This technology advancement represents a major step forward for next-generation computing platforms, immersive AR/VR systems, and high-efficiency, advanced power devices. By expanding silicon carbide to 300mm, Wolfspeed is unlocking new performance thresholds and manufacturing scalability for some of the world’s most demanding semico
ExaGrid’s FY 2025 Results—A Record Quarter and a Record Year for Company13.1.2026 14:00:00 CET | Press Release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it had record bookings and record revenue in the fourth quarter ending December 31, 2025, and had a record-year for bookings and revenue for 2025. ExaGrid broke many records in the quarter (Q4 2025), including: Record overall revenue and bookings Record revenue and bookings for new customers Record revenue and bookings for existing customer repeat orders Record 202 new logo customers in the quarter Record 88 six-figure new logo customers 3 seven-figure new logo customer deals In addition, ExaGrid had a record bookings and revenue year in 2025 and remained P&L, EBITDA, and free cash flow positive for the 20th consecutive quarter. The company is 100% debt-free, demonstrating strong financial health as a company. ExaGrid added 202 n
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 14:00:00 CET | Press Release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom